The U.S. government will provide GlaxoSmithKline and Sanofri with $2.1 billion to produce and supply the government with 100 million of COVID-19 vaccine as part of the Warp Speed program. Half of the funds will be used to develop the vaccine itself and conduct clinical trials. The rest of the money will be used to increase production and supply of the original 100 million doses.
The U.S. government will provide GlaxoSmithKline and Sanofri with $2.1 billion to produce and supply the government with 100 million of COVID-19 vaccine as part of the Warp Speed program. Half of the funds will be used to develop the vaccine itself and conduct clinical trials. The rest of the money will be used to increase production and supply of the original 100 million doses. 
gsk.com
English (US) 